FOLH1 and prostate cancer: Meijer et al. [37] showed improved oncological outcomes for patients who received pre-SRT PSMA PET/CT in biochemically recurrent prostate cancer; patients without PSMA PET/CT had a biochemical progression rate of 21% after one year, compared to 8% with pre-SBRT PSMA PET/CT.